Wanbury Ltd. (BSE: 524212) is a Navi Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹674 Cr, it ranks #1,820 by market cap among the 6,137 Indian listed companies on FinBizNet, and #27 of 63 in Pharmaceuticals. At ₹178.47 (as of 25 Oct 2026), the share price is 50.3% below its 52-week high of ₹358.85 and 10.5% above its 52-week low of ₹161.50. The share price is down 23.2% over one year and down 46.2% over three months.
| Current Price | ₹178.47 |
|---|---|
| Market Cap | ₹674 Cr |
| BSE Code | 524212 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 9.6 |
| Return on Equity | 64.92% |
| Return on Assets | 12.40% |
| 52-Week Range | ₹161.50 – ₹358.85 |
| 1-Year Price Change | -23.2% |
| 3-Month Price Change | -46.2% |
| Beta (1Y) | 0.47 |
| Dividend Yield | 0.00% |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.wanbury.com |
| Revenue | ₹166 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 2.0% |
| EPS (Basic) | ₹0.93 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
1. Pharmaceuticals and Related Products-This segment manufactures and sells formulations and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Wanbury Ltd. | ₹674 Cr | 9.6 | 64.92% | ₹166 Cr | -23.2% |
Listed by market capitalisation. Ratios are shown for context only.
Wanbury Ltd. is trading at ₹178.47, with a market capitalisation of ₹674 Cr.
Wanbury Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Wanbury Ltd. has a P/E of 9.6 and a return on equity of 64.92%.
Wanbury Ltd. is listed on the BSE under the scrip code 524212.
Wanbury Ltd.'s share price is down 23.2% over one year and down 46.2% over three months. Its 52-week range is ₹161.50 to ₹358.85.
In Q1 FY27, Wanbury Ltd. reported revenue of ₹166 Cr and net profit of ₹3 Cr, with basic EPS of ₹0.93 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.